评论 {{commentNum}}
avatar
{{ item.user.nickName }}
{{ item.auditTime }}
{{ item.content }}
评论
删除
{{ reply.content }}
回复
删除
avatar
{{userInfo.nickName}} {{userInfo.nickName}}
{{userInfo.userAuthName}}
{{userInfo.userAuthName}}
136
文章
1.5m
阅读
40k
粉丝
私信
相关推荐
Communication from the Commission �Guideline on the operation of the procedures laid down in Chapters II, III and IV of Commission Regulation (EC) No 1234/2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products
0阅读
 · 
0点赞
INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION Communication from the Commission �Guideline on the details of the various categories of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products
0阅读
 · 
0点赞
Regulatory Actions; Electronic applications for marketing authorisations for medicinal products
0阅读
 · 
0点赞
Marketing Authorization of Veterinary Medicinal Products in Poland
0阅读
 · 
0点赞
Summary of European Union decisions on marketing authorisations in respect of medicinal products
0阅读
 · 
0点赞
Selected Biological Medicinal Products and Their Veterinary Use
0阅读
 · 
0点赞
Marketing Authorisation Expenses for Veterinary Medicinal Products in Northern Europe
0阅读
 · 
0点赞
Cyphenothrin (Veterinary Medicinal Products)
0阅读
 · 
0点赞
Regulatory Actions; Committee for Medicinal Products for Veterinary Use
0阅读
 · 
0点赞
Regulatory Actions; Committee for Medicinal Products for Veterinary Use
0阅读
 · 
0点赞
找对属于你的技术圈子
回复「进群」加入官方微信
为你推荐
  • The main responsibility of marketing authorization holder in drug change management in the new situation [新形势下药品上市许可持有人在药品变更管理中的主体责任]
  • Analysis of China regulatory strategy on post-approval changes of pharmaceutical products [我国药品上市后变更的监管思路]
  • Analysis of China regulatory strategy on post-approval changes of pharmaceutical products [我国药品上市后变更的监管思路]
  • Analysis of China regulatory strategy on post-approval changes of pharmaceutical products [我国药品上市后变更的监管思路]
  • Analysis of China regulatory strategy on post-approval changes of pharmaceutical products [我国药品上市后变更的监管思路]
  • 药品物流的发展
  • 致美国众议院 科技与太空委员会 能源环境与调查监督小组委员会的书面陈述
  • 老年人瓶装药品的包装设计分析
  • 全国分析检测人员能力培训委员会
  • 关于一种新的面部痤疮外用药的临床试验的结果
    • {{viewlikeslist.praiseCount}}点赞
    {{viewlikeslist.rewardCount}}赞赏
    {{viewlikeslist.collectCount}}收藏
    {{viewlikeslist.treadCount}}踩     {{viewlikeslist.marketCount}}分享
    注册登录即表示同意 登录注册协议 和 隐私政策
    请用微信扫码支付

    订单金额：¥{{payAmount}}

    支付即代表已阅读并同意 《支付说明》

    赞赏作者的才华

    {{userInfo.nickName}}
    {{ item }}
    确认微信支付